| 4.28 0.05 (1.18%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.19 | 1-year : | 8.63 |
| Resists | First : | 6.15 | Second : | 7.38 |
| Pivot price | 4.87  |
|||
| Supports | First : | 4.16 | Second : | 3.46 |
| MAs | MA(5) : | 4.33 |
MA(20) : | 5.18 |
| MA(100) : | 4.33 |
MA(250) : | 2.8 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 5.2 |
D(3) : | 4.5 |
| RSI | RSI(14): 28.8 |
|||
| 52-week | High : | 9.39 | Low : | 1.17 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ APLT ] has closed above bottom band by 20.0%. Bollinger Bands are 2.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.45 - 4.47 | 4.47 - 4.5 |
| Low: | 4.19 - 4.21 | 4.21 - 4.23 |
| Close: | 4.24 - 4.28 | 4.28 - 4.31 |
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Mon, 15 Apr 2024
Applied Therapeutics Welcomes Dale Hooks as New CCO - TipRanks.com - TipRanks
Mon, 01 Apr 2024
Is Applied Therapeutics Inc (APLT) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Thu, 28 Mar 2024
US FDA extends review of Applied Therapeutics' genetic disease drug - Reuters
Wed, 13 Mar 2024
Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why - Yahoo Finance
Mon, 11 Mar 2024
Applied Therapeutics Reveals Strategy and Positive Trial Update - TipRanks.com - TipRanks
Fri, 08 Mar 2024
Applied Therapeutics Inc (APLT) Announces Year-End 2023 Financial Results and Clinical Progress - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 106 (M) |
| Held by Insiders | 8.49e+007 (%) |
| Held by Institutions | 7.1 (%) |
| Shares Short | 4,330 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.453e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 3 % |
| Return on Assets (ttm) | 149.6 % |
| Return on Equity (ttm) | -86.6 % |
| Qtrly Rev. Growth | 9.99e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -55 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -38.74 |
| Dividend | 0 |
| Forward Dividend | 4.98e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|